Iran Press/ Middle East: Last month, CanSino's co-founder said the company was in talks with Russia, Brazil, Chile, and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV.
The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body.
Researchers said last month that CanSino's vaccine, co-developed with China's military research unit, appeared to be safe and induced immune responses in most subjects.
Saudi Arabia plans to test the vaccine alongside a placebo on 5,000 volunteers and is currently preparing trials in the cities of Riyadh, Dammam, and Mecca, Saudi state news agency SPA said on Saturday.
205/216
Read more:
Chinese vaccine successfully enters third phase of clinical trial
